G1 Therapeutics Inc $ 23.18 0.11 (0.48%)
Volume:
1,642,079
Avg Vol (1m):
1,721,484
Market Cap $:
964.02 Mil
Enterprise Value $:
784.47 Mil
PE Ratio:
0.00
PB Ratio:
4.91
Financial Strength | 6/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Cash-To-Debt | 7.47 | ||
Equity-to-Asset | 0.78 | ||
Debt-to-Equity | 0.16 | ||
Debt-to-EBITDA | -0.29 | ||
Piotroski F-Score | 3 | ||
Altman Z-Score | 8.5 | ||
Beneish M-Score | 0 | ||
WACC vs ROIC |
Profitability Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
Operating Margin % | -213.04 | ||
Net Margin % | -219.18 | ||
ROE % | -46.66 | ||
ROA % | -38.72 | ||
ROC (Joel Greenblatt) % | -821.19 | ||
3-Year EBITDA Growth Rate | 9 | ||
3-Year EPS without NRI Growth Rate | 9.8 |
GTHX
Valuation Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
PB Ratio | 4.91 | ||
PS Ratio | 19.25 | ||
EV-to-EBIT | -8.11 | ||
EV-to-EBITDA | -8.16 | ||
EV-to-Revenue | 17.34 | ||
Current Ratio | 9.23 | ||
Quick Ratio | 9.23 | ||
Days Sales Outstanding | 1.91 |
Dividend & Buy Back |
Current | Vs Industry | Vs History | |
---|---|---|---|
3-Year Average Share Buyback Ratio | -10.1 |
Valuation & Return |
Current | Vs Industry | Vs History | |
---|---|---|---|
Price-to-Tangible-Book | 4.93 | ||
Earnings Yield (Greenblatt) % | -12.36 |